-- Robert Preidt
WEDNESDAY, June 5 (HealthDay News) -- The discovery of a genetic
variation that affects how some black patients respond to the blood
thinner warfarin could improve the safety and effectiveness of the
drug, researchers report.
Blacks with this common genetic variation need a significantly
lower dose of warfarin than those without the variation, the
researchers report online June 4 in
"Adding this genetic marker -- found in more than 40 percent of African-American patients in the study -- to standard dosing algorithms improved the predictability of warfarin dosing by 21 percent in these individuals, which has the potential to increase the safety and effectiveness of this notoriously hard-to- dose drug," study leader Julie Johnson, of the University of Florida, said in a journal news release.
Warfarin is widely used to prevent blood clots in patients with
a heart rhythm disorder called atrial fibrillation, a history of
previous blood clots and after major surgery. However, it can be
difficult to determine the correct dose for individual
Previous research has identified two genes that explain about 30
percent of the difference in warfarin response in people of
European and Asian ancestry, but these genes have less of an effect
In this study, the researchers analyzed health information and
DNA samples from hundreds of blacks and determined that there was a
strong association between the rs12777823 variant on chromosome 10
and warfarin dose. The findings suggest that the dose of warfarin
required by blacks with one or two copies of this variant is about
7 milligrams (mg) to 9 mg less per week than for other patients,
the researchers said.
The U.S. Food and Drug Administration advocates use of genetic
backgrounds to help guide warfarin dosing, Mark Alberts, of the
University of Texas Southwestern Medical Center at Dallas and
author of an accompanying editorial, said in the news release.
"However, the practical aspects [and limitations] have not been
"Genetic testing has several challenges: it is not widely available in some areas; it is costly; and clinicians often can identify the correct dose before test results are available. If these problems were corrected, the actual use of such tests might increase substantially," Alberts noted.
The American Heart Association has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.